ArticleExpert opinion on investigational drugs2022
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.
Open access · greenAbstract read
In one paragraph
Article in Expert opinion on investigational drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis.Infection and drug resistance · 2026Review
- Structural and Functional Insights into Viral and Fungal Proteins Involved in Chronic Inflammation and Their Biologic Treatments.Pharmaceutics · 2025Review
- In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species.Mycoses · 2025Article
- Exploring fungal survival mechanisms: toward next-generation antifungal therapies against Candida spp.Archives of microbiology · 2025Review
- Rezafungin Utilisation in Real Life-FungiScope Results From Europe and the United States.Mycoses · 2025Article
- A phase 1 open label study to assess the human mass balance and metabolite profile ofAntimicrobial agents and chemotherapy · 2024Article
- Insights from Three Pan-European Multicentre Studies on Invasive Candida Infections and Outlook to ECMM Candida IV.Mycopathologia · 2024Review
- Mechanism and bioinformatics analysis of the effect of berberine-enhanced fluconazole against drug-resistant Candida albicans.BMC microbiology · 2024Article
- Invasive candidiasis.Nature reviews. Disease primers · 2024Review
- Candida parapsilosis complex in the clinical setting.Nature reviews. Microbiology · 2024Review
- Article
- Observational
- Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia.The Journal of antimicrobial chemotherapy · 2023Article
- Treatment of Invasive Aspergillosis: How It's Going, Where It's Heading.Mycopathologia · 2023Review
- Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap.The Lancet. Microbe · 2023Review
- Fungal Drug Response and Antimicrobial Resistance.Journal of fungi (Basel, Switzerland) · 2023Review
- Antifungal Development and the Urgency of Minimizing the Impact of Fungal Diseases on Public Health.ACS bio & med chem Au · 2023Review
- Metagenomic Next-Generation Sequencing of Plasma for Diagnosis of COVID-19-Associated Pulmonary Aspergillosis.Journal of clinical microbiology · 2023Article
- Reason and reality-identifying barriers to patient enrolment for clinical trials in invasive candidiasis.The Journal of antimicrobial chemotherapy · 2022Article
- Liposomal amphotericin B-the future.The Journal of antimicrobial chemotherapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 12 institutions in 5 countries.
Martin HoeniglDivision of Infectious Diseases, Excellence Center for Medical Mycology (ECMM), Medical University of Graz, Graz, Austria.ORCID 0000-0002-1653-2824
Rosanne Spruteof Internal Medicine, Excellence Center for Medical Mycology (ECMM)University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I , Cologne, Germany.
Amir ArastehfarCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
John R PerfectDivision of Infectious Diseases and Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Cornelia Lass-FlörlInstitute of Hygiene and Medical Microbiology, Excellence Center for Medical Mycology (ECMM), Medical University of Innsbruck, Innsbruck, Austria.
Romuald BellmannClinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0003-2861-3258
Juergen PrattesDivision of Infectious Diseases, Excellence Center for Medical Mycology (ECMM), Medical University of Graz, Graz, Austria.
George R ThompsonDepartment of Internal Medicine, Division of Infectious Diseases and Department of Medical Microbiology and Immunology, University of California Davis Medical Center, Sacramento, United States.
Nathan P WiederholdDepartment of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Mohanad M Al ObaidiDivision of Infectious Diseases, University of Arizona College of Medicine, Tucson, AZ, USA.
Birgit WillingerDivision of Clinical Microbiology, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Maiken C ArendrupUnit of Mycology, Statens Serum Institut, Copenhagen, Denmark.ORCID 0000-0002-4747-0144
Philipp Koehlerof Internal Medicine, Excellence Center for Medical Mycology (ECMM)University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I , Cologne, Germany.ORCID 0000-0002-7386-7495
Matteo Oliverioof Internal Medicine, Excellence Center for Medical Mycology (ECMM)University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I , Cologne, Germany.
Matthias EggerDivision of Infectious Diseases, Excellence Center for Medical Mycology (ECMM), Medical University of Graz, Graz, Austria.
Ilan S SchwartzDivision of Infectious Diseases, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Oliver A Cornelyof Internal Medicine, Excellence Center for Medical Mycology (ECMM)University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I , Cologne, Germany.ORCID 0000-0001-9599-3137
Peter G PappasDepartment of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.
Robert KrauseDivision of Infectious Diseases, Excellence Center for Medical Mycology (ECMM), Medical University of Graz, Graz, Austria.
University of Cologne · DEMedical University of Graz · ATInnsbruck Medical University · ATDuke Medical Center · USHackensack Meridian Health · USMedical University of Vienna · ATStatens Serum Institut · DKThe University of Texas Health Science Center at San Antonio · USUniversity of Alabama at Birmingham · USUniversity of Alberta · CAUniversity of Arizona · USUniversity of California Davis Medical Center · US
Funding
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3MNCATS NIH HHS UL1 TR001442
Abstract
introductionThe epidemiology of invasive AREAS COVERED: The authors shed light on those antifungal agents active against EXPERT OPINION: Ibrexafungerp and fosmanogepix have novel mechanisms of action and will provide effective options for the treatment of
Indexed as
Candidiasis, InvasiveDrugs, InvestigationalAntifungal AgentsCandidaCandidiasisDrug Resistance, FungalHumansMicrobial Sensitivity TestsAntifungal AgentsDrugs, InvestigationalactivityantiinfectiveAntimycoticAPX001ATI-2307CD101fosmanogepixibrexafungerpmanogepixMAT2203miltefosineNP-339oteseconazoleresistancerezafunginSCY-078trialsVL-2397VT-1161
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.